- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | bioAffinity launches study to test lung cancer diagnostic | 2 | Investing.com | ||
| 17.02. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.02. | bioAffinity Technologies expands medical advisory board with lung experts | 3 | Investing.com | ||
| 04.02. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 22.12.25 | bioAffinity Technologies meldet Eigentümerwechsel bei Village Oaks Pathology | 2 | Investing.com Deutsch | ||
| 19.12.25 | bioAffinity Technologies vertagt außerordentliche Hauptversammlung mangels Quorum | 3 | Investing.com Deutsch | ||
| 19.12.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | bioAffinity Technologies: EPS verfehlt Schätzungen um 4,65 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 14.11.25 | bioAffinity Technologies GAAP EPS of -$4.74, revenue of $1.45M | 1 | Seeking Alpha | ||
| 14.11.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | bioAffinity reports 111% increase in lung cancer test volume | 4 | Investing.com | ||
| 05.11.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10.25 | bioAffinity receives Australian patent acceptance for lung disease test | 2 | Investing.com | ||
| 28.10.25 | bioAffinity erhält australische Patentzusage für Test zur Lungengesundheit | 1 | Investing.com Deutsch | ||
| 28.10.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10.25 | Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? | 8 | Benzinga.com | ||
| 16.10.25 | bioAffinity stock soars after receiving patent allowance for AI lung cancer test | 1 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,381 | -2,56 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,390 | -3,20 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,060 | -6,99 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,430 | +3,37 % | Onco-Innovations Limited: Onco-Innovations Announces Amendment to Private Placement Pricing | Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / February 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H... ► Artikel lesen | |
| CYBIN | 6,550 | +7,38 % | Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee | In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes... ► Artikel lesen | |
| BIOLINERX | 2,160 | -1,37 % | BioLineRx Ltd. - 6-K, Report of foreign issuer | ||
| BIOARCTIC | 28,060 | -3,97 % | Number of shares and votes in BioArctic AB (publ) as of February 27, 2026 | STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares... ► Artikel lesen | |
| NUCANA | 2,100 | -0,94 % | NuCana plc: NuCana Appoints Theresa Bruce as Chief Operating Officer | EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes... ► Artikel lesen | |
| GENSIGHT BIOLOGICS | 0,085 | -0,70 % | GenSight Biologics S.A.: GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments | Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing... ► Artikel lesen | |
| IMMUNOME | 22,250 | +1,74 % | Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development | ||
| PEPGEN | 6,490 | +4,68 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| QIAGEN | 41,295 | -0,23 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| BIONTECH | 92,80 | -0,54 % | BioNTech SE: BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 24. Februar 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 10. März 2026, die Ergebnisse für das vierte Quartal und... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,815 | +1,18 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,500 | +4,40 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen |
Das Unternehmen BIOAFFINITY TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.